Physician profile
Emilio Suarez
NPI 1043245749
$9,932.58
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,782 · 2020: $1,741 · 2021: $1,864 · 2022: $378 · 2023: $27.80 · 2024: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,043.37 | 2019-2024 | Intracept, Rezum Generator |
| Vertiflex, INC. | $1,251.80 | 2019 | |
| Amgen INC. | $900.92 | 2019-2021 | |
| Horizon Therapeutics Plc | $482.18 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $469.57 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $424.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.33 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $356.62 | 2019-2021 | |
| Nevro Corp. | $335.04 | 2019-2024 | Senza |
| Forte Bio-Pharma LLC | $267.23 | 2020-2022 | |
| Lilly USA, LLC | $238.87 | 2019-2021 | |
| Pfizer INC. | $209.29 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $204.93 | 2021 | |
| Almatica Pharma LLC | $137.10 | 2021 | |
| Zyla Life Sciences, INC. | $126.33 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $112.31 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.87 | 2019-2020 | |
| Vertos Medical, INC. | $96.30 | 2021 | |
| Daiichi Sankyo INC. | $86.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.05 | 2019-2021 | |
| Biogen, INC. | $68.72 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $67.55 | 2019-2020 | |
| Nalu Medical, INC. | $51.60 | 2021 | |
| Medline Industries Lp | $47.78 | 2022 | |
| Osprey Medical INC | $47.36 | 2021 | |
| Medtronic, INC. | $46.55 | 2021 | |
| Abbott Laboratories | $41.52 | 2019-2020 | |
| Si-Bone, INC. | $39.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.56 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.50 | 2019 | |
| Kaleo, INC. | $26.79 | 2019 | |
| Medtronic USA, INC. | $22.91 | 2019 | |
| Allergan, INC. | $18.95 | 2020 | |
| Pacira Therapeutics, INC. | $17.20 | 2019 | |
| Shionogi INC | $17.12 | 2019 | |
| Abbvie INC. | $15.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.